Mr. Cola was most recently President of Shire plc’s Specialty Pharmaceuticals business, where he oversaw all aspects of this $2.5 billion enterprise. He joined Shire in 2005 as Executive Vice President of Global Therapeutic Business Units and Portfolio Management. Previously he was with Safeguard Scientifics, where he served as President of the Life Sciences Group. While at Safeguard Scientifics, Mr. Cola served as Chairman and CEO of Clarient, a cancer diagnostics company acquired by GE Healthcare, and as Chairman of Laureate Pharma, a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca.Mr. Cola received a BA in biology and physics from Ursinus College and an MS in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals, NuPathe and Pennsylvania BIO, the statewide association representing the bioscience community. He also serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia. "It is an honor to lead Medgenics at this exciting time in the company’s development," stated Mr. Cola. "Our company is built upon a potential breakthrough technology in gene therapy and protein production that represents a safe and reversible approach that also shows promise to individually dose the production of therapeutic proteins. I am particularly pleased to have Garry and John joining me. Having worked with each of them in the past, I know they have the skills and leadership to advance our gene therapy and protein therapeutics technology and build a successful company. Following a thorough review of our assets and target markets, we look forward to rolling out our team’s strategy and advancing Medgenics into what promises to be an exciting future." Dr. Leaman brings to Medgenics more than a decade of corporate strategy, finance, venture capital and M&A experience in the life sciences industry. Most recently he was Vice President of Commercial Assessment at Shire plc, with responsibility for the strategic assessment of licensing and M&A opportunities, including Shire’s acquisition of SARcode Bioscience. Prior to joining Shire in 2011, Dr. Leaman was a Principal at Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies, where he oversaw the fund’s investment and corporate board duties in life science investments including Proteon Therapeutics, Inc., Inotek Pharmaceuticals Corp., ZS Pharma, Inc. and MicuRx Pharmaceuticals, Inc. Prior to that, he was an Associate Principal at McKinsey & Company, where he provided consulting services to senior management of several top 20 pharmaceutical companies including M&A and corporate finance, payer/reimbursement strategies and strategic product development.
Dr. Leaman received an M.D. and an MBA from the University of Pennsylvania’s School of Medicine and Wharton School, respectively. He received a degree in Psychology, Philosophy and Physiology at Oriel College, University of Oxford, while completing a Rhodes scholarship. Dr. Leaman received a BS in biology from Elizabethtown College.Dr. Neil has more than 30 years of clinical development experience in the life sciences industry. Most recently he was a Partner at Apple Tree Partners, a life sciences private equity fund. Prior to joining Apple Tree Partners in 2012, he was Corporate Vice President of Science & Technology at Johnson & Johnson, and Group President at Johnson & Johnson Pharmaceutical Research and Development. He held senior positions at AstraZeneca, EMD Pharmaceuticals and Merck KGaA. Under his leadership, a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals. Dr. Neil holds a BS from the University of Saskatchewan and an M.D. from the University of Saskatchewan, College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He serves on the Boards of Reagan Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board. In connection with these three appointments, the Compensation Committee of the Medgenics Board of Directors has granted Mr. Cola, Dr. Leaman and Dr. Neil inducement awards consisting of stock options covering up to 1,500,000, 800,000 and 900,000 shares, respectively, of the company’s common stock, $0.0001 par value per share (Common Stock), at a per share exercise price of $4.22, or, based on an exchange rate of £1=US$1.59 ,265 pence per share representing the closing price of the Common Stock on the grant date. These options have a 10-year term, with one-third of the options vesting on the first anniversary of grant and the balance vesting in equal increments on a monthly basis over the following two years, subject to the respective officer’s continuous service through each vesting date. The Compensation Committee of Medgenics’ Board of Directors, which is comprised solely of independent directors, granted this award on September 13, 2013 pursuant to stand-alone award agreements outside of Medgenics’ Stock Incentive Plan as inducements material to Mr. Cola’s, Dr. Leaman’s and Dr. Neil’s acceptance of their appointments to the company in accordance with Section 711 of the NYSE MKT Company Guide.
Also on September 13, 2013, the Compensation Committee of the Medgenics Board of Directors granted stock options covering up to 400,000 shares of Common Stock to Sol J. Barer, the Chairman of the company’s Board of Directors, as compensation for his efforts in connection with the executive search process and his continuing oversight of the management transition. These options have a 10-year term , with one-third of the options vesting on each of the first three anniversaries of grant and have an exercise price of US$5.22 or, based on an exchange rate of £1=US$1.59 ,328 pence per share, being $1.00 above the closing price of the Common Stock on the day of the grant. This award was made under the Medgenics’ Stock Incentive Plan previously approved by the company’s stockholders. This announcement is included pursuant to the London Stock Exchange’s AIM Rules for Companies admitted to trading on the AIM market (the AIM Rules).Following the grant of options to Dr. Barer and Mr. Cola, the interests of these directors in the company are as follows:
|Common Shares||% of Issued Share Capital||Instrument||Number||Expiry Date||Exercise Price||Total Interests||% of Fully Diluted Share Capital|
|Michael Cola (Director; CEO and Pres.)||-0-||0.0%||Options||1,500,000||13/9/2023||$4.22||1,500,000||4.4%|
In accordance with Schedule 2(g) of the AIM Rules, the following information in relation to the appointment of Mr. Cola to the Medgenics Board of Directors is disclosed:Mr. Cola is 54 years old. Mr. Cola is currently a director of the following:
- NuPathe Inc.
- Vanda Pharmaceuticals Inc.
- Pennsylvania BIO
- Boys & Girls Clubs of Philadelphia